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Introduction
Juvenile dermatomyositis is a rare autoimmune disease
characterised by profound muscle weakness in addition
to skin lesions, calcinosis, and underlying vasculopathy.
Current treatment plans, including methotrexate and
corticosteroids, are ineffective in some patients and may
be associated with significant adverse events. The bene-
fits and risks of etanercept in JDMS are not well studied.
Objectives
The aim of this study is to review the benefit and safety
of etanercept in JDMS patients.
Methods
We performed a single centre retrospective analysis of all
consecutive JDMS patients treated with etanercept in a
tertiary paediatric referral centre. Data collected included
clinical and laboratory data, disease duration, the initial
dose of etanercept, and other medication details. The
outcome was measured by the Childhood Myositis
Assessment Scale (CMAS) scored before commencing
Etanercept and at 12 months follow-up.
Results
Seven JDMS patients (5 female) were treated with
etanercept. Median age at diagnosis was 64 months
(36-103 months). The most frequent symptoms at diag-
nosis included proximal muscle weakness in all patients,
constitutional features in 6, muscle pain in 5, typical
skin features in 4, and arthralgia in 3 patients.
Disease duration until etanercept was 35 months
(10-60 months). All children were treated with predniso-
lone and methotrexate prior to commencing etanercept
and continued prednisolone (in reducing doses) and
methotrexate concurrently.
Median duration on etanercept was 20 months (range
6-85 months). Five children ceased etanercept; three due
to a flare of disease activity, one child due to transfer of
care, and one child due to disease remission. Two
patients still receive etanercept at time of analysis. Two
children who ceased etanercept commenced monthly
infliximab therapy with marked disease improvement.
The median CMAS score before etanercept was
44 (range 41-47), and at 12 months after commencing
etanercept the median CMAS was 46 (range 41-53).
Conclusion
Etanercept did not demonstrate an appreciable or reliable
improvement in the disease control of JDMS. Whilst bene-
ficial for some patients, caution should be taken when
initiating etanercept for JDMS. Further multicenter studies
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